The natural history of primary biliary cirrhosis

Seminars in Liver Disease

Volumn 34, Issue 3, 2014, Pages 329-333

  Imam, Mohamad H ^a   Lindor, Keith D ^b  

^a UND School of Medicine & Health Sciences Southeast Campus   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

liver transplantation; primary biliary cirrhosis; ursodeoxycholic acid

Indexed keywords

URSODEOXYCHOLIC ACID; CHOLAGOGUE;

ARTICLE; ASCITES; DISEASE COURSE; DRUG TREATMENT FAILURE; HEPATIC ENCEPHALOPATHY; HISTORY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEDICAL HISTORY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PREGNANCY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RECURRENT DISEASE; STOMACH DISEASE; TREATMENT RESPONSE; VARICOSIS; FEMALE; IMMUNOLOGY; INTRAHEPATIC BILE DUCT; LIVER CIRRHOSIS, BILIARY; MALE; PATHOLOGY; TIME; TREATMENT OUTCOME;

BILE DUCTS, INTRAHEPATIC; CHOLAGOGUES AND CHOLERETICS; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; MALE; PREGNANCY; TIME FACTORS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84904986329     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1383731     Document Type: Article

References (44)

1. Lee J., Belanger A., Doucette J. T., Stanca C., Friedman S., Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol: 2007; 5 11 1313 1315
2. Mendes F. D., Kim W. R., Pedersen R., Therneau T., Lindor K. D. Mortality attributable to cholestatic liver disease in the United States. Hepatology: 2008; 47 4 1241 1247
3. Poupon R., Chrétien Y., Poupon R. E., Ballet F., Calmus Y., Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet: 1987; 1 8537 834 836
4. Prince M. I., James O. F. The epidemiology of primary biliary cirrhosis. Clin Liver Dis: 2003; 7 4 795 819
5. Matsumoto H. Mechanism of the pivot shift. J Bone Joint Surg Br: 1990; 72 5 816 821
6. Kaplan M. M., Gershwin M. E. Primary biliary cirrhosis. N Engl J Med: 2005; 353 12 1261 1273
7. Kitic I., Boskovic A., Stankovic I., Prokic D. Twelve-year-old girl with primary biliary cirrhosis. Case Rep Pediatr: 2012; 2012 937150
8. Kim W. R., Lindor K. D., Locke G. R. III., et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology: 2000; 119 6 1631 1636
9. James O. F., Bhopal R., Howel D., Gray J., Burt A. D., Metcalf J. V. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology: 1999; 30 2 390 394
10. Baldursdottir T. R., Bergmann O. M., Jonasson J. G., Ludviksson B. R., Axelsson T. A., Björnsson E. S. The epidemiology and natural history of primary biliary cirrhosis: a nationwide population-based study. Eur J Gastroenterol Hepatol: 2012; 24 7 824 830
11. Lindor K. D., Gershwin M. E., Poupon R., Kaplan M., Bergasa N. V., Heathcote E. J. American Association for Study of Liver Diseases Primary biliary cirrhosis. Hepatology: 2009; 50 1 291 308
12. Solis Herruzo J. A., Solis Munoz P., Munoz Yague T. The pathogenesis of primary biliary cirrhosis. Revista Espanola de Enfermedades Digestivas Organo Oficial de la Sociedad Espanola de Patologia Digestiva: 2009; 101 413 423
13. McNally R. J., James P. W., Ducker S., James O. F. Seasonal variation in the patient diagnosis of primary biliary cirrhosis: further evidence for an environmental component to etiology. Hepatology: 2011; 54 6 2099 2103
14. Varyani F. K., West J., Card T. R. An increased risk of urinary tract infection precedes development of primary biliary cirrhosis. BMC Gastroenterol: 2011; 11 95
15. Chen R. C., Naiyanetr P., Shu S. A., et al. Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology: 2013; 57 4 1498 1508
16. Sasaki M., Kakuda Y., Miyakoshi M., Sato Y., Nakanuma Y. Infiltration of inflammatory cells expressing mitochondrial proteins around bile ducts and in biliary epithelial layer may be involved in the pathogenesis in primary biliary cirrhosis. J Clin Pathol: 2014; 67 6 470 476
17. Corpechot C., Gaouar F., Chrétien Y., Johanet C., Chazouillères O., Poupon R. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol: 2012; 56 1 218 224
18. Hirschfield G. M., Liu X., Xu C., et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med: 2009; 360 24 2544 2555
19. Jin Q., Moritoki Y., Lleo A., et al. Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology: 2012; 55 5 1495 1506
20. Dinani A. M., Fischer S. E., Mosko J., Guindi M., Hirschfield G. M. Patients with autoimmune hepatitis who have antimitochondrial antibodies need long-term follow-up to detect late development of primary biliary cirrhosis. Clin Gastroenterol Hepatol: 2012; 10 6 682 684
21. Mattalia A., Quaranta S., Leung P. S., et al. Characterization of antimitochondrial antibodies in health adults. Hepatology: 1998; 27 3 656 661
22. Gatselis N. K., Zachou K., Norman G. L., et al. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity: 2013; 46 7 471 479
23. Rudic J. S., Poropat G., Krstic M. N., Bjelakovic G., Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev: 2012; 12 CD000551
24. Zhang Y., Lu J., Dai W., et al. Combination therapy of ursodeoxycholic acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis. Gastroenterol Res Pract: 2013; 2013 490731
25. Ozaslan E., Efe C., Heurgue-Berlot A., et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. Clin Gastroenterol Hepatol: 2014; 12 5 863 869
26. Levy C., Naik J., Giordano C., et al. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics. Clin Gastroenterol Hepatol: 2013
27. Boberg K. M., Wisloff T., Kjollesdal K. S., Stovring H., Kristiansen I. S. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment Pharmacol Ther: 2013; 38 7 794 803
28. Papastergiou V., Tsochatzis E. A., Rodriquez-Peralvarez M., et al. Biochemical criteria at 1. -year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. Aliment Pharmacol Ther: 2013; 38 11-12 1354 1364
29. Carbone M., Mells G. F., Pells G., et al UK PBC Consortium Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology: 2013; 144 3 560 569, e7, quiz e13-e14
30. Kuiper E. M., Hansen B. E., Adang R. P., et al. Dutch PBC Study Group. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol: 2010; 22 12 1495 1502
31. Myers R. P., Swain M. G., Lee S. S., Shaheen A. A., Burak K. W. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol: 2013; 108 6 933 941
32. Lens S., Leoz M., Nazal L., et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int: 2014; 34 2 197 203
33. Trivedi P. J., Kumagi T., Al-Harthy N., et al. Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis. Clin Gastroenterol Hepatol: 2013
34. Neuberger J. Liver transplantation for primary biliary cirrhosis. Autoimmun Rev: 2003; 2 1 1 7
35. Carbone M., Bufton S., Monaco A., Griffiths L., Jones D. E., Neuberger J. M. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study. J Hepatol: 2013; 59 3 490 494
36. Neuberger J., Portmann B., Macdougall B. R., Calne R. Y., Williams R. Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med: 1982; 306 1 1 4
37. Liermann Garcia R. F., Evangelista Garcia C., McMaster P., Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology: 2001; 33 1 22 27
38. Charatcharoenwitthaya P., Pimentel S., Talwalkar J. A., et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl: 2007; 13 9 1236 1245
39. Sanchez E. Q., Levy M. F., Goldstein R. M., et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation: 2003; 76 11 1583 1588
40. Levitsky J., Hart J., Cohen S. M., Te H. S. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl: 2003; 9 7 733 736
41. Khettry U., Anand N., Faul P. N., et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl: 2003; 9 1 87 96
42. Sebagh M., Farges O., Dubel L., Samuel D., Bismuth H., Reynes M. Histological features predictive of recurrence of primary biliary cirrhosis after liver transplantation. Transplantation: 1998; 65 10 1328 1333
43. Manousou P., Arvaniti V., Tsochatzis E., et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl: 2010; 16 1 64 73
44. Silveira M. G., Talwalkar J. A., Lindor K. D., Wiesner R. H. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant: 2010; 10 4 720 726